Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot (ENGAGED)
Early Investigation of Glucose Monitoring After Gestational Diabetes (ENGAGED): Utility and Acceptability of Continuous Glucose Monitoring in the Early Postpartum Period After Gestational Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Rachel Gordon, MD, MPH
- Phone Number: 614-293-7980
- Email: rachel.gordon@osumc.edu
Study Contact Backup
- Name: Seuli Brill, MD
- Phone Number: 614-293-7980
- Email: seuli.brill@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Medical Center
-
Contact:
- Rece Foss
- Phone Number: 614-293-8000
- Email: rece.foss@osumc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women with a viable singleton intrauterine pregnancy
- Able to understand the study, and having understood, provide written informed consent in English
- Recent pregnancy affected by gestational diabetes
Exclusion Criteria:
- Pregestational Diabetes (Type I or Type II)
- Continued use of diabetes medications (including metformin and insulin) immediately after delivery
- Preterm delivery (< 37 weeks gestation)
- Twin or higher order gestation
- No access to a smartphone
- Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic
- Participation in this trial in a prior pregnancy
- History of skin allergy to adhesive products or CGM
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Participants
Participants will be recruited at 6-8 weeks postpartum; at that appointment, CGMs will be placed.
After wearing the CGM, participants will fill out surveys regarding their experience.
At 10-12 weeks postpartum, they will complete the standard of care OGTT as well as complete an interview regarding their experience.
At 12 months postpartum, they will complete a blood test to check their hemoglobin A1c.
|
At 11-14 months postpartum, participants will be asked to have their blood drawn to check their hemoglobin A1c to look for signs of developed insulin resistance
At 10-12 weeks postpartum, participants will complete an oral glucose tolerance test, which involves drinking a glucose substance and having glucose levels measured a maximum of 3 times.
CGMs will be worn for a maximum of 10 days at 6-8 weeks postpartum.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability of CGM
Time Frame: 15 weeks from enrollment
|
As determined by survey
|
15 weeks from enrollment
|
|
Comparative experience of OGTT and CGM
Time Frame: 15 weeks from enrollment
|
As determined by survey
|
15 weeks from enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence and characteristics of dysglycemia in GDM postpartum
Time Frame: 15 weeks from enrollment
|
As determined by survey
|
15 weeks from enrollment
|
|
Lifestyle changes survey
Time Frame: 15 weeks from enrollment
|
Breastfeeding practices, changes in diet and physical activity
|
15 weeks from enrollment
|
|
Medical care
Time Frame: 15 weeks from enrollment
|
Number of doctor's visits (both for participant and their infant), prescribed medications
|
15 weeks from enrollment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Infant outcomes
Time Frame: birth outcomes only
|
in-hospital medical record review
|
birth outcomes only
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Endocrine System Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Metabolic Diseases
- Pregnancy Complications
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Nutritional and Metabolic Diseases
- Diabetes, Gestational
- Hyperglycemia
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Blood Chemical Analysis
- Clinical Chemistry Tests
- Diagnostic Techniques, Endocrine
- Glucose Tolerance Test
Other Study ID Numbers
Other Study ID Numbers
- 2023H0066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.